May 15, 2020
Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020
May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
May 05, 2020
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial
Apr 17, 2020
U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
Mar 04, 2020
Lipocine Announces TLANDO(TM) PDUFA Date of August 28, 2020
Feb 27, 2020
Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants
Feb 24, 2020
Lipocine Announces Regulatory Path Forward for TLANDO(TM) Resubmission
Feb 11, 2020
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
Dec 09, 2019
BioTE Medical Founder and Chairman Warns of Potential Serious Impact on Women's Health from Recent Position Statement on Women's Testosterone Therapy Lasting Generations
Nov 18, 2019
Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants
Nov 13, 2019
Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants
Nov 11, 2019
Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA
Oct 01, 2019
Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019
Sep 30, 2019
First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144
Aug 27, 2019
Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction
Aug 05, 2019
State Leader in Bioidentical Hormone Replacement Therapy, The Youth Institute, Expands Their Practice to the Queen City
Jul 23, 2019
Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population
Jul 10, 2019
Women's Excellence Now Offers Comprehensive Menopause Care
Jun 25, 2019
Hormone Replacement Therapy (HRT): Global Market Strategy Report 2016-2024 - Transdermal HRT Products Present Exciting Opportunities
May 14, 2019
Lipocine Announces TLANDO(TM) NDA PDUFA Action Date of November 9, 2019